In vivo models of thrombosis for the antiphospholipid syndrome

Lupus

Volumn 5, Issue 5, 1996, Pages 451-455

  Pierangeli, S S ^a   Harris, E N ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Murine model of thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; PHOSPHOLIPID ANTIBODY; POLYCLONAL ANTIBODY;

ANIMAL MODEL; ANTIPHOSPHOLIPID SYNDROME; CONFERENCE PAPER; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOSIS;

EID: 0029807655     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339600500524     Document Type: Conference Paper

References (48)

1. Harris EN, Pierangeli SS. Antiphospholipid antibodies and the Antiphospholipid Syndrome. Springer Sem Immunopathol 1994; 16: 223-245.
2. Harris EN. Annotation: antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9.
3. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-280.
4. Harris EN. Syndrome of the Black Swan. Br J Rheumatol 1987; 26: 324-326.
5. Harris EN et al. Anti-cardiolipin antibodies detection by radioimmunoassay and association with thrombosis. Lancet 1983; ii: 1211-1214.
6. Harris EN et al. Anti-cardiolipin antibodies in autoimmune thrombocytopenia purpura. Br J Haematol 1985; 59: 231-234.
7. Hughes GRV, Harris EN, Gharavi AE. The anti-cardiolipin syndrome. J Rheumatol 1986; 13: 486-489.
8. Asherson RA. A 'primary' antiphospholipid syndrome?. J Rheumatol 1988; 15: 1742-1746.
9. Harris EN et al. Thrombosis, recurrent fetal loss, and thrombocytopenia: predictive value of IgG anticardiolipin antibodies. Arch Intern Med 1986; 146: 2153-2156.
10. Alving BM, Barr CF, Tang DB. Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin times. Am J Med 1990; 88: 112-116.
11. Lockshin MD, Qamar T, Druzin M, Goei S. Antibody to cardiolipin, lupus anticoagulant, and fetal death. J Rheumatol 1987; 14: 259-262.
12. Loizou S et al. Association of quantitative anti-cardiolipin antibody levels with fetal loss. Quart J Med 1988; 68: 525-531.
13. Comp PC, Debault LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with non-specific anticoagulants. Blood 1983; 62: 299a.
14. Freyssinet JM et al. An IgM lupus anticoagulant that reutilizes the enhancing effect of phospholipid on purified thrombomodulin activity A mechanism for thrombosis. Thromb Haemost 1986; 55: 309-313.
15. Cariou R et al. Effect of the lupus anticoagulant on antithrombogenic properties of endothelial cells-inhibition of thrombomodulin dependent protein C activation. Thromb Haemost 1985; 60: 54-58.
16. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-2432.
17. Martinuzzo ME, Maclouf J, Carreras LO, Levy-Toledano S. Antiphospholipid antibodies enhance thrombin induced platelet activation and thromboxane formation. Thromb Haemost 1993; 70: 667-671.
18. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effect of anticardiolipin antibodies from patients with the Antiphospholipid Syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995; 73 (3): 529-524.
19. 2-glycoprotein 1 is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 297-300.
20. Branch DW et al. IgG fraction from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal death. Am J Obtet Gynecol 1990; 163: 420.
21. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci USA 1991; 88: 3069-3073.
22. Mendlovic S et al. Induction of systemic lupus erythematosus-like diseases by a common human antiDNA idiotype. Proc Natl Acad Sci USA 1988; 85: 2260-2264.
23. Bakimer R et al. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody. J Clin Invest 1992; 89: 1558-1563.
24. Sthoeger ZW, Tartakovsky B, Bentwich Z, Mozes E. Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome. J Clin Immunol 1993; 13: 127-138.
25. Fishman P et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interlekin-3. J Clin Invest 1993; 91: 1834-1837.
26. 2-glycoprotein 1) induces experimental APS in naive mice. Arthr Rheum 1993; 36 (9): S134.
27. 2-GP1) does not cause fetal death. Am J Obstet Gynecol 1995; 173: 1410-1415.
28. Smith HR, Hansen CL, Rose R, Canoso RT. Autoimmune MRL/lpr/lpr mice are an animal model for the secondary antiphospholipid syndrome. J Rheumatol 1990; 17: 911-915.
29. Stockmans F et al. Continuous quantitative monitoring of mural thrombus kinetics in the crushed rat femoral vein. Thromb Haemost 1991; 65: 425-431.
30. Pierangeli SS et al. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost 1994; 71 (5): 670-674.
31. Pierangeli SS et al. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the Antiphuspholipid Syndrome. Thromb Haemost 1995; 74. 1361-1367.
32. Olee T et al. A monoclonal IgG anticardiolipin antibody from a patient with Antiphospholipid Syndrome is thrombogenic in mice Proc Natl Acad Sci USA 1996 (in press).
33. 2-glycoprotein 1 (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124.
34. 2-glycoprotein 1 enhances cardiolipin binding activity but is not the target antigen for antiphospholipid antibodies. Br J Haematol 1992; 82: 565-570.
35. Sammaritano LR, Lockshin MD, Gharavi AE. Antiphospholipid antibodies differ in aPL cofactor requirement Lupus 1992; 1: 51-56.
36. 2-glycoprotein 1. J Clin Invest 1992; 90: 1105-1109.
37. 2-glycoprotein 1 or anticardiolipin antibodies alone. Clin Exp Immunol 1993; 93 (2): 269-272.
38. Nimpf J, Wurm H, Kostner GM. 2glycoprotein 1 (apo H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987; 63: 109.
39. 2-glycoprotein 2 and human IgG antiphospholipid antibodies. Circulation 1996 (in Press).
40. Rosove MH, Brewer PMC. Antiphospholipid thrombosisL clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-308.
41. Derksen RHWM, deGroot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993; 52: 689-692.
42. Khamashta MA et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995; 332 (15): 993-997.
43. Carter A, Eban R. Prevention of postoperative deep venous thrombosis in legs by orally administered hydroxychloroquine sulphate. Brit Med J 1974; 3: 94-95.
44. Johnson R, Green J, Charnley J. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement. Clin Orthop 1977; 127: 123-132.
45. Knisely M, Bloch E. Microscopic observations of intravascular agglutination of red cells and consequent sludging of blood in human diseases. Anat Rec 1942; 82: 426.
46. Madow B. Use of antimalarial drugs as 'desludging agents in vascular disease processes'. J Amer Med Assoc 1990; 172: 1630-1833.
47. Petri M et al. Incidence of and predictors of thrombotic events in SLE: protective role of hydroxychloroquine. Arthr Rheum 1992; 35 (suppl 9): S54.
48. Wallace D. Does hydroxychloroquine sulphate prevent clot formation in systemic lupus erythematosus?. Arthrit Rheum 1987; 30: 1435-1436 (letter)